Confronting 
neurodegeneration

To improve the lives of patients and their families.

To provide medicines that slow, stop, or revert the progression.

By targeting the pathology of toxic misfolded proteins.

Our Programs

Structured for Success

Based in the biotech hub of San Diego, our in-house expertise of our people and global collaborations with academic and industry partners allow us to discover novel therapeutic targets and develop innovative therapeutics.  


About Our Team

News

Neuropore Therapies (NPT) Announces Appointment of Dr. Errol DeSouza as President and Chief Executive Officer January 23, 2017

Neuropore Therapies, Inc. announced today that Errol De Souza, Ph.D. has been appointed President and Chief Executive Officer effective immediately.

See All News

NPTTM Publications

Neuropore publishes paper describing the discovery and characterization of a small molecule compound targeting α-synuclein as a potential Parkinson’s disease therapeutic October 5th, 2016

Report in Brain, describes findings supporting the hypothesis that NPTTM100-18A reduces alpha-synuclein toxicity through a novel mechanism that involves displacing pathological alpha-synuclein from the membrane.

See All Publications

 

Our Major Partnerships

Ever Neuro Pharma
The Michael J. Fox Foundation for Parkinson's Research
UCB
Neuropore Video

Our Technology

Learn about Neuropore’s two part development strategy targeting misfolded proteins -- the key pathological culprit(s) underlying neurodegenerative disorders.

Learn More See All Videos